Tweet
Pregnant women who took the antiviral drugs oseltamivir (Tamiflu) and zanamivir (Relenza) during pregnancy did not have an increased risk of adverse neonatal outcomes, according to a study of European registries.
Instead, exposure to neuraminidase inhibitors was linked with a slightly reduced risk of low birth weight (adjusted odds ratio 0.77, 95% CI 0.65-0.91) and giving birth to a small for gestational age infant (adjusted OR 0.72, 95% CI 0.59-0.87), reported Sophie Graner, MD, of Karolinska Institutet in Sweden, and colleagues.
This study included the period of the 2009-2010 influenza A/H1N1 pandemic, the authors noted, when the number of women who took neuraminidase inhibitors during pregnancy "increased markedly" compared with previous years, they wrote in BMJ.
...
Instead, exposure to neuraminidase inhibitors was linked with a slightly reduced risk of low birth weight (adjusted odds ratio 0.77, 95% CI 0.65-0.91) and giving birth to a small for gestational age infant (adjusted OR 0.72, 95% CI 0.59-0.87), reported Sophie Graner, MD, of Karolinska Institutet in Sweden, and colleagues.
This study included the period of the 2009-2010 influenza A/H1N1 pandemic, the authors noted, when the number of women who took neuraminidase inhibitors during pregnancy "increased markedly" compared with previous years, they wrote in BMJ.
...
Comment